Validation of the 2023 International Diagnostic Criteria for MOGAD in a Selected Cohort of Adults and Children

Validation of the 2023 International Diagnostic Criteria for MOGAD in a Selected Cohort of Adults and Children

To test the performance of the 2023 myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) criteria in adults and children with inflammatory demyelinating conditions who were tested for MOG antibodies (Abs). This was a retrospective study of patients tested for MOG-Abs from 2018 to...

Full description

Saved in:
Bibliographic Details
Published in:Neurology Vol. 103; no. 1; p. e209321
Main Authors: Varley, James A, Champsas, Dimitrios, Prossor, Timothy, Pontillo, Giuseppe, Abdel-Mannan, Omar, Khaleeli, Zhaleh, Petzold, Axel, Toosy, Ahmed T, Trip, Sachid A, Wilson, Heather, Mallon, Dermot H, Hemingway, Cheryl, Mankad, Kshitij, Loon Chou, Michael Kin, Church, Andrew J, Hart, Melanie S, Lunn, Michael P, Brownlee, Wallace, Hacohen, Yael, Ciccarelli, Olga
Format: Journal Article
Language:English
Published: United States 09-07-2024
Subjects:
Adolescent
Adult
Aged
Autoantibodies - blood
Child
Child, Preschool
Cohort Studies
Female
Humans
Infant
Magnetic Resonance Imaging
Male
Middle Aged
Myelin-Oligodendrocyte Glycoprotein - immunology
Retrospective Studies
Sensitivity and Specificity
Young Adult
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To test the performance of the 2023 myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) criteria in adults and children with inflammatory demyelinating conditions who were tested for MOG antibodies (Abs). This was a retrospective study of patients tested for MOG-Abs from 2018 to 2022 in 2 specialist hospitals. The inclusion criteria comprised ≥1 attendance in an adult or pediatric demyelinating disease clinic and complete clinical and MRI records. The final clinical diagnosis of MOGAD, made by the treating neurologist, was taken as the benchmark against which the new criteria were tested. The international MOGAD diagnostic criteria were applied retrospectively; they stipulate at least 1 clinical or MRI supporting feature for MOGAD diagnosis in positive fixed MOG cell-based assay without a titer. The performance MOG-Ab testing alone for MOGAD diagnosis was also assessed and compared with that of MOGAD criteria using the McNemar test. Of the 1,879 patients tested for MOG-Abs, 539 (135 pediatric and 404 adults) met the inclusion criteria. A clinical diagnosis of MOGAD was made in 86/539 (16%) patients (37 adults, 49 children), with a median follow-up of 3.6 years. The MOGAD diagnostic criteria had sensitivity of 96.5% (adults 91.9%, children 100%), specificity of 98.9% (adults 98.8%, children 98.9%), positive predictive value of 94.3% (adults 89.4%, children 98%), negative predictive value of 99.3% (adults 99.2%, children 100%), and accuracy of 98.5% (adults 98.3%, children 99.2%). When compared with MOG-Ab testing alone, a difference was seen only in adults: a significantly higher specificity (98.9% vs 95.6%, = 0.0005) and nonstatistically significant lower sensitivity (91.9% vs 100%, = 0.08). The international MOGAD diagnostic criteria exhibit high performance in selected patients with inflammatory demyelinating diseases (who had a high pretest probability of having MOGAD) compared with best clinical judgment; their performance was better in children than in adults. In adults, the MOGAD criteria led to an improvement in specificity and positive predictive value when compared with MOG-Ab testing alone, suggesting that the requirement of at least 1 clinical or MRI supporting feature is important. Future work should address the generalizability of the diagnostic criteria to cohorts of greater clinical diversity seen within neurologic settings.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
ISSN:0028-3878
1526-632X
1526-632X
DOI:10.1212/WNL.0000000000209321